Results 1 to 10 of about 50 (40)
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
Tangri N, Falcone El
+16 more sources
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
+13 more sources
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +3 more sources
Stent thrombosis and drug-eluting stents [PDF]
Journal of Cardiology, 2011 Coronary stents have been used for the treatment of patients with coronary artery disease (CAD), and significantly improved procedural safety and are associated with a lower rate of restenosis compared with balloon angioplasty alone. Drug-eluting stents (DES) have been dominant for the treatment of CAD with efficacy in significantly reducing both ...
Takafumi Hiro +2 more
openaire +3 more sources
Drug-eluting stent in diabetes [PDF]
Sao Paulo Medical Journal, 2007 Long-term evaluation of cardiovascular risk among diabetic patients has shown that the incidence of death due to myocardial infarction among these patients is 20%, whereas among nondiabetic patients it is only 3.5%. Such observations haveled to classifying diabetes as a risk that is equivalent to establi shed coronary artery disease.
Walter J. Gomes +4 more
openaire +4 more sources
Coronary Artery Disease, 2019 Approximately, 10-20% of patients with drug eluting stent (DES) in-stent restenosis (ISR) will develop recurrent ISR; yet, the optimal management of recurrent DES-ISR is unknown. We sought to compare the outcomes of recurrent DES-ISR treated with drug eluting balloons (DEB) to those with repeated implantation of new-generation DES.A total of 172 ...
Guozhong Wang +5 more
openaire +3 more sources
The future of drug-eluting stents
Pharmacological Research, 2008 This review aims to provide a glimpse into the future of drug-eluting stents (DES). Since their arrival in 2002, DES have transformed the practice of interventional cardiology by drastically reducing restenosis and the need for repeat revascularization.
Joost Daemen +3 more
openaire +2 more sources
Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis?∗
Journal of the American College of Cardiology, 2015 In 2001, when Morice et al. [(1)][1] presented the initial results of RAVEL (The Randomized Study With the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions), showing 0% angiographic restenosis 6 months after ...
Neil Ruparelia, Antonio Colombo
openaire +3 more sources
The future of drug eluting stents [PDF]
Heart, 2006 In-stent restenosis (ISR) is the major drawback of percutaneous coronary interventions, occurring in 10-40% of patients. Drug eluting stents (DES) are successful in a large majority of patients in preventing restenosis for the first year after implantation.
Anis, RR, Karsch, KR
openaire +4 more sources
Drug eluting coronary stents [PDF]
BMJ, 2002 Percutaneous coronary revascularisation has revolutionised the treatment of ischaemic heart disease during the past two decades. Despite technical refinements, however, long term results after using standard techniques remain limited by the phenomenon of restenosis—a process whereby elastic recoil and neointimal hyperplasia occur at the site of ...
B D Prendergast, M Thomas, N P Jenkins
openaire +3 more sources